Demis Hassabis, cofounder of DeepMind and 2024 Nobel Laureate, talks to Fortune about his AI drug discovery startup, ...
The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...
Isomorphic Labs CEO Demis Hassabis discusses $600M funding round, plans for a US office, and expanding into ...
Google’s artificial intelligence arm DeepMind has been holding back the release of its world-renowned research, as it seeks ...
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...
Demis Hassabis, a childhood chess prodigy, said his experience with the game afforded him his first brush with AI. He was ...
Explore more
The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...
Demis, who was last year jointly awarded the Nobel Prize in Chemistry with Google DeepMind colleague Dr John Jumper for their ...
The drug discovery company, which has partnerships with Eli Lilly and Novartis, is developing AI models to design drugs and ...
AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...
AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding ...
The search giant should’ve been first to the chatbot revolution. It wasn’t. So it punched back with late nights, layoffs—and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results